Home  »  Finance   »  TARS: Riding the Market Waves of Growth and Declin...

TARS: Riding the Market Waves of Growth and Decline in 2023

The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 10.10%.However, over the last six months, we can see a weaker performance of 20.27%. Over the last 30 days, the price of TARS has leaped by -3.76%. And in the last five days, it has surged by 0.56%.

At present, Tarsus Pharmaceuticals Inc. (TARS) has a stock price of $16.14. In the previous session, the stock saw a rise, peaking at $16.24 after an opening price of $14.82. The day’s lowest price was $14.82, and it closed at $14.75.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Tarsus Pharmaceuticals Inc. experienced a rather shaky stock market performance. The highest value in the past year was recorded at $25.25 on 07/24/23 and the lowest value was $11.33 on 04/17/23.

52-week price history of TARS Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Tarsus Pharmaceuticals Inc.’s current trading price is -36.08% away from its 52-week high, while its distance from the 52-week low is 42.45%. The stock’s price range during this period has varied between$11.33 and $25.25. The Tarsus Pharmaceuticals Inc.’s shares, which operate in the Healthcare, saw a trading volume of around 1.39 million for the day, a figure considerably higher than their average daily volume of 0.43 million over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Tarsus Pharmaceuticals Inc. (TARS) has experienced a quarterly decline of -13.32% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 481.13M and boasts a workforce of 87 employees.

Tarsus Pharmaceuticals Inc.: Analysts’ Ratings Unveiled

As of right now, 7 analysts are rating Tarsus Pharmaceuticals Inc. as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 17.40, with a change in price of +1.52. Similarly, Tarsus Pharmaceuticals Inc. recorded 349,749 in trading volume during the last 100 days, posting a change of +10.40%.

TARS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TARS stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.17.

TARS Stock Stochastic Average

Tarsus Pharmaceuticals Inc.’s raw stochastic average for the past 50 days is presently 14.38%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 48.42%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 18.66% and 24.88%, respectively.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts